No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PTCT PTC Therapeutics
- 25.410
- -0.560-2.16%
Close Apr 23 16:00 ET
- 24.920
- -0.490-1.93%
Post 16:52 ET
1.95BMarket Cap-3035P/E (TTM)
26.270High25.165Low754.37KVolume26.160Open25.970Pre Close19.28MTurnover1.34%Turnover RatioLossP/E (Static)76.61MShares59.84052wk High-2.38P/B1.44BFloat Cap17.53052wk Low--Dividend TTM56.48MShs Float78.720Historical High--Div YieldTTM4.26%Amplitude4.030Historical Low25.561Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an...
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics Price Target Maintained With a $45.00/Share by Cantor Fitzgerald
PTC Therapeutics Price Target Maintained With a $45.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $45 Price Target
PTC to Announce Fiscal Q2'24 Results on Wednesday, May 1st, 2024
BOSTON, April 10, 2024 /PRNewswire/ -- PTC (Nasdaq: PTC) will release its fiscal 2024 second quarter results on Wednesday, May 1st after the stock market closes. Senior management will host a live we
Comments
PTC Therapeutics' low P/S ratio is seen as reasonable due to industry underperformance. However, weak revenue outlook is pressuring shares, making maintaining current prices challenging. Shareholders accept the low P/S, expecting no future revenue surprises.
There's No Escaping PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Muted Revenues Despite A 27% Share Price RiseRecent insider selling at PTC Therapeutics outweighs insider buying, a potential bearish sign. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership suggests alignment with shareholders, but insider selling warrants caution.
1
PTC Therapeutics' ongoing losses may have led to negative market view, causing a contradictory movement in the stock against the company’s revenue growth. The firm's underperformance in the past five years suggests unresolved issues. Currently, the healthcare company has five investment analysis warning signs.
$PTC Therapeutics(PTCT.US$ 🚀🚀🚀🚀🚀🚀🚀🔥🔥🔥🔥🔥🔥🔥 Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- R...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg